Yuhan Corporation (000100.KS)
- Previous Close
73,200.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 84,190.48 - Volume
0 - Avg. Volume
502,031 - Market Cap (intraday)
5.338T - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Apr 24, 2024 - Apr 29, 2024
- Forward Dividend & Yield 450.00 (0.61%)
- Ex-Dividend Date Dec 27, 2023
- 1y Target Est
79,454.00
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; and Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury. The company also provides ETC products, such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems, as well as anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. In addition, it offers over-the-counter (OTC) products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; veterinary drugs; and household and healthcare products. Further, the company provides dental care products. Additionally, it manufactures and sells animal medicines and feeds; and provides contract manufacturing services. The company was founded in 1926 and is headquartered in Seoul, South Korea.
www.yuhan.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000100.KS
Performance Overview: 000100.KS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000100.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000100.KS
Valuation Measures
Market Cap
5.40T
Enterprise Value
5.28T
Trailing P/E
40.33
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.95
Price/Book (mrq)
2.64
Enterprise Value/Revenue
2.84
Enterprise Value/EBITDA
28.46
Financial Highlights
Profitability and Income Statement
Profit Margin
7.32%
Return on Assets (ttm)
1.34%
Return on Equity (ttm)
6.52%
Revenue (ttm)
1.86T
Net Income Avi to Common (ttm)
136.09B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
322B
Total Debt/Equity (mrq)
10.95%
Levered Free Cash Flow (ttm)
-131.96B
Research Analysis: 000100.KS
Company Insights: 000100.KS
000100.KS does not have Company Insights